A Phase 1b Randomized, Placebo-Controlled, Delayed-Start Trial of UB-312 in Synucleinopathies.
Objective: Assess safety and immunogenicity of UB-312 in a phase 1b trial in Multiple System atrophy (MSA) or Parkinson’s disease (PD). Background: Abnormal deposition of…SNCA Antisense Oligonucleotide for Multiple System Atrophy: HORIZON Trial Update
Objective: To provide an update on the baseline demographics and safety from the HORIZON Clinical Trial of ION464 Background: Multiple System Atrophy (MSA) is a…Long-term Safety of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension
Objective: To assess the long-term safety and tolerability of ampreloxetine in patients with synucleinopathies (MSA, PD, and PAF) and symptomatic neurogenic orthostatic hypotension (nOH) from…Determinants of care partner burden in atypical parkinsonian syndromes
Objective: To understand the determinants of burden among people caring for individuals diagnosed with progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), or multiple system atrophy…Short-term effect of continuous positive airway pressure in MSA patients with sleep disordered breathing
Objective: SBD are frequent in MSA, mainly represented by inspiratory stridor, obstructive and central sleep apnea/hypopnea syndrome (SAS), or hypopneaimpacting the quality of sleep. A…An Analysis of Subgroups of Multiple System Atrophy Patients from Ampreloxetine Phase 3 Trials
Objective: To present results in the subset of patients with multiple system atrophy (MSA) and relevant MSA subgroups from two ampreloxetine phase 3 trials for…Therapy-associated risk decision making in individuals with multiple system atrophy and Parkinson’s disease, THE YAMSA TRIAL
Objective: This study aimed to quantify the risk willingness of patients suffering from the α-synucleinopathies multiple system atrophy (MSA) and Parkinson's Disease (PD) and identify…Use of levodopa-carbidopa intestinal gel to treat a patient with multiple system atrophy (MSA)
Objective: To describe a case report on the use of Levodopa-carbidopa intestinal gel (LCIG) to treat non-motor symptoms in a patient with multiple system atrophy (MSA) Background: There is no…UMSARS versus laryngoscopy-based assessment of dysphagia
Objective: To compare the Unified Multiple System Atrophy Rating Scale (UMSARS) part I-item 2 with an ear/nose/throat (ENT) expert physician assessment. Background: Early and severe…Identifying a path to improve diagnostic delay and access to care for PSP, CBS, and MSA
Objective: To understand diagnosis and care experiences of patients and care partners living with progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 7
- Next Page »